Immunotech Laboratories Signs Funding Agreement With Curing Capital, Inc.

        Print
| Source: Immunotech Laboratories

MONROVIA, Calif., May 28, 2013 (GLOBE NEWSWIRE) -- Immunotech Laboratories, Inc. (Pink Sheets:IMMB) Immunotech Laboratories, Inc. today released the following company updates for shareholders and Investors:

Immunotech Founder, President & Chief Scientific Officer, Harry Zhabilov today stated, "The company signed a funding agreement with 'Curing Capital, Inc.' an established Capital Venture Company with over 100 years combined Banking and Investment experience by the company's management Team."

Curing Capital, Inc. will provide the following services in its role as investment consultant.

Assistance in developing and updating a comprehensive Business Plan and Executive Summary.

Additionally Curing Capital will provide best efforts to introduce funding sources whose goal will be to secure up to $30,000,000 in long term financing through equity, or debt, or combination of both equity and debt. For Immunotech Laboratories, Inc.

Mr. Zhabilov further commented, "This is a positive breakthrough for Immunotech's continued Research and Treatment development of Terminal diseases such as the Aids & HIV virus."

Further information about Immunotech's patented "IPF"can be obtained from www.immunotechlab.com

About Curing Capital,Inc

Curing Capital is a consulting firm that specializes in introducing private and public companies to a network of funding sources ranging from Venture Capitalists (VCs), Investment Bankers (IBs) to Angels and High Net Worth Investors. We have also helped companies with other financial requests such as business plan development, Investor Relations, Public Relations, 211 filings and preparing private companies who wish to go public. The Curing Capital team has over 100 years of investment banking experience combined. www.curingcapital.com

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Company Contact: 
Public  Relations:
The Nabors Group: 713-875-9200
E-mail: 
www.facebook.com/Naborsgroup